Acorda Therapeutics shares plunged 37 percent on Wednesday after the drugmaker said that will had paused enrolling patients in two key trials testing its Parkinson’s disease drug following patient deaths.
Acorda said there has been seven cases of sepsis in patients taking tozadenant inside the study, including its mid-stage trial, out of which 5 patients died.
Tozadenant belongs to a completely new class of drugs called A2a receptor antagonists that will can help improve motor symptoms in patients with Parkinson’s disease.
The company said that will continues to expect to report data through the late-stage trial inside the first quarter of 2018.
The drugmaker came under investor pressure to pursue a sale in August, after a judge in March struck down key patents of its multiple sclerosis drug Ampyra, which accounts for almost all of its revenue.